[Randomization of a population for a clinical trial of immunization against the human immunodeficiency virus (HIV)].
Serum HIV antibodies has been investigated in different subpopulation from four different regions in Zäire by Elisa (Elavia Pasteur) and Western Blot. Seropositive prevalence differed from 2.4% (rural population) to 12.5% (urban population) according to the regions. When the group with 2.4% migrated to the area with 12.5% positives, after 8-12 months the number of seropositives in this group raised to 8%, showing an increase of 5.6% within one year. Such population is suitable for a large scale clinical trial (with anti-AIDS vaccine) to be performed on individuals with high risk of natural infection.
Dechazal
L
L
Médecin Chef de l'A.M.T. Française, Kinshasa, Zaïre.
Goussard
B
B
Salaun
J J
JJ
Bernard
J
J
Zagury
D
D
D015492:AIDS Serodiagnosis; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D015153:Blotting, Western; D002986:Clinical Trials as Topic; D015023:Democratic Republic of the Congo; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D014765:Viral Vaccines / Q000302:isolation & purification
D014765:Viral Vaccines
Randomisation d'une population pour un essai clinique d'immunisation contre le virus de l'immunodeficience humaine (VIH).